Evidence map›Paper›PMID 42304522›Full record

ArticleInfectious diseases of poverty2026

Rapid drug susceptibility testing of Mycobacterium tuberculosis against first-line drugs simultaneously all-in-one plate by using a novel high-sensitive reporter phage combined with the BACTEC MGIT 960 system.

Ruiqing Ma, Ying Zhang, Minghua Zhu, Muyang Zhang, Chengcheng Qian, Juan Wu, Zhidong Hu, Mingquan Guo, Xiao-Yong Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruiqing Ma *Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Ying Zhang *Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Minghua Zhu *Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Muyang ZhangShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Chengcheng QianAffiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.
Juan WuShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Zhidong HuShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China.
Mingquan GuoShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China. gmqjiandan@163.com.
Xiao-Yong FanShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, 201508, China. xyfan008@fudan.edu.cn.

Funding

National Natural and Science Foundation of China 32470998National Natural and Science Foundation of China 32500151National Natural and Science Foundation of China 92469203Prevention and Control of Emerging and Major Infectious Diseases, China 2025ZD01907500Science and Technology Commission of Shanghai Municipality, China 23YF1436200Shanghai Municipal Health Bureau, China 20214Y0089Shanghai Municipal Health Bureau, China 2022XD060
6 · The paper itself

Abstract

backgroundReporter phage assay offers a low-cost and rapid approach for drug susceptibility testing (DST) of Mycobacterium tuberculosis (Mtb). However, their adoption in clinical laboratories has been limited by challenges such as low detection sensitivity and operational complexity. To address these challenges, we integrated a novel reporter phage into the clinical laboratory workflow for DST of Mtb.

methodsA novel high-sensitive reporter phage, ΦLSN, was constructed by integrating promoter P

resultsWhen tested against 62 Mtb clinical isolates for susceptibility to first-line anti-tuberculosis drugs (rifampicin, isoniazid, streptomycin, and ethambutol), the ΦLSN DST assay showed sensitivities of 93.8%, 96.4%, 100%, and 80%, and specificities of 100%, 97.1%, 100%, and 100%, respectively. Moreover, preliminary prospective validation against 131 positive MGIT cultures demonstrated that the ΦLSN DST assay achieved sensitivities of 87.5%, 100%, 100%, and 100%, and specificities of 100%, 99.1%, 99.1%, and 99.1% for the four first-line anti-TB drugs within 72 h.

conclusionThe integration of the BACTEC MGIT 960 with the ΦLSN DST assay provides a high-efficiency and low-cost method for TB DST simultaneously against multiple drugs within 3 days only, presenting potential to enhance the diagnosis and management of drug-resistant TB, especially in the resource-limited regions.

Indexed as

Antitubercular AgentsBacteriophagesMycobacterium tuberculosisGenes, ReporterHumansMicrobial Sensitivity TestsMycobacteriophagesRapid Diagnostic TestsSensitivity and SpecificityAntitubercular AgentsDrug susceptibility testingMycobacterium tuberculosisReporter phage

Identifiers

PMID42304522
PMCPMC13270915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.